000999 · SZSE · China
999.com.cnFinancials as of FY2025
Makes traditional Chinese medicine products to pharmaceutical-grade standards and sells them through China's hospitals and pharmacies.
What this company is and how it runs — written from structure, not news.
China Resources Sanjiu Medical & Pharmaceutical manufactures traditional Chinese medicine formulations to the same exacting standards as conventional drugs, running herbal extraction and tableting through a single facility that is simultaneously certified under two separate NMPA approval pathways — one for TCM and one for synthetic pharmaceuticals. Because the Chinese Pharmacopoeia requires specific active-compound ratios that can only come from domestically grown herbs, the company must qualify each geographic growing region as a supplier through years of batch-consistency monitoring before a single extra kilogram of raw material can enter the production line. Those consistent ratios are what allow hospital procurement departments and pharmacy chains to treat the products as standardized dosage forms, which is the condition for getting onto provincial formularies and into national drug pricing negotiations — so the entire revenue base depends on the herbal supply network holding steady. The vulnerability sits at that same point: if the government shifts TCM reimbursement rules or pushes NMPA standards toward international export requirements, the active-compound specifications that the dual approval and the supplier qualification history were built around would need to be rewritten, and neither the regulator nor the growing seasons would move quickly enough to soften the disruption.
How does this company make money?
The company earns money by selling traditional Chinese medicine products and over-the-counter pharmaceuticals to wholesale distributors, who then supply pharmacy chains and hospital procurement systems across China. The price it can charge for each unit is shaped by China's national drug pricing negotiations and by whether the product has been included in provincial hospital formularies — so getting onto those lists directly affects how much revenue each product generates.
What makes this company hard to replace?
The knowledge needed to reproduce the company's extraction methods and active-compound ratios is embedded in years of manufacturing practice and cannot simply be transferred to a new producer quickly. Switching to a different supplier would mean starting fresh on herbal supplier qualification, which takes multiple years of batch-consistency monitoring before the Chinese Pharmacopoeia standards can be met. Any new manufacturer attempting to enter this space also faces the NMPA's TCM-pathway approval process, which cannot be accelerated regardless of resources.
What limits this company?
The company can add more production lines and equipment to make more products, but it cannot speed up the supply side. Each region of China where herbs are grown produces different quality grades, and every supplier must go through years of batch-consistency checks before they can be relied upon. That qualification process cannot be shortened by spending more money, so the herbal supply network is the hard ceiling on how fast the business can grow.
What does this company depend on?
The company cannot operate without National Medical Products Administration manufacturing licences for pharmaceutical production in China. It relies on herbal extract suppliers whose output meets Chinese Pharmacopoeia specifications — and those relationships take years to build. Its Good Manufacturing Practice-certified facilities must stay compliant for both TCM and conventional drug production. China Resources Group, its state-owned enterprise parent, provides the capital access needed to build and maintain that dual-standard setup. Operational permits for its Shenzhen manufacturing base are also a direct dependency.
Who depends on this company?
Chinese retail pharmacy chains would lose access to TCM formulations made to pharmaceutical-grade standards, since few other manufacturers hold the same dual approvals. Hospital systems across China would face supply gaps for over-the-counter digestive and respiratory products already written into treatment protocols. Traditional medicine practitioners would lose the standardized dosage forms that let them prescribe TCM therapies at consistent strengths.
How does this company scale?
Adding production lines and equipment can increase the volume of finished tablets and formulations relatively quickly. What does not scale at the same pace is the herbal supply base — each geographic growing region requires its own supplier qualification process, with ongoing monitoring of batch consistency, and there is no way to rush that process by installing more machinery.
What external forces can significantly affect this company?
The biggest outside pressure is government policy: if China shifts how it integrates traditional medicine into national healthcare coverage, reimbursement eligibility for TCM products could change overnight. Regulatory harmonization — pressure to align China's traditional medicine standards with international pharmaceutical export rules — could force costly reformulations for any products the company wants to sell outside China. On the demand side, China's aging population is increasing the number of people seeking digestive and respiratory care, which are categories this company supplies heavily through TCM formulations.
Where is this company structurally vulnerable?
If the Chinese government decided to cut traditional Chinese medicine from national reimbursement coverage, or if it rewrote NMPA traditional medicine standards to align with international pharmaceutical export rules, the active-compound specifications that underpin every product approval would need to be reworked. That would unwind the regulatory foundation the dual-pathway approval and the entire supplier qualification network were built on.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Three observations describe the present configuration: the fast moving average sits below the slow moving average, the company has been profitable for three years, and cash-flow margin is elevated.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
What the company actually pays, and whether its own cash supports it.
The reported statements, read against the company's own industry.
5 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Four observations co-occur: free cash flow positive each of the last three fiscal years, revenue increased each of the last three fiscal years, trailing-statistics OCF margin elevated, and book value increased each of the last four fiscal years. The configuration describes multi-year fundamental persistence across cash flow, top line, margin, and equity accumulation.
Three observations align: revenue has increased every year over the trailing three years, receivables have increased every year over the trailing four years, and operating cash flow margin is on the industry-benchmarked scale. The picture is concurrent growth in revenue and receivables with peer-relative cash-conversion context.
Is this company growing?
Three multi-year observations co-occur: revenue increased year-over-year in each of the last three fiscal years, gross profit (absolute level) increased year-over-year in each of the last four fiscal years, and net income was positive in each of the last five fiscal years. The configuration describes growth-and-profitability persistence across three different windows.
How is this stock valued?
Three observations co-occur: price is several standard deviations below its one-year mean, the company has reported positive net income every year for three years, and book value has increased every year for four years. The set describes a depressed-price profile alongside fundamental stability and equity accumulation.
Three observations co-occur: price is several standard deviations below its one-year mean, the company has reported positive net income every year for three years, and the equity ratio is in the elevated industry-benchmarked range. The configuration describes a depressed-price, profitable, equity-funded profile.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph